BDX
insider transactionsBECTON DICKINSON & CO — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-6.8K
0 buy · 6.8K sell
Net value · 365d
-$1.1M
$0 in · $1.1M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
10
0 buy · 6.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
EVP & Pres Med.Essntl&BioPharm · 10b5-1
$166.6K
1.1K sh · $151.48
Own -7%
-
Grant·A
Peter Menziuso KEY
EVP and President, BDI
$0
14.3K sh
Own New
-
Exercise·M
Chairman, CEO and President · 10b5-1
$0
20.2K sh
Own New
-
Sell·S
Chairman, CEO and President · 10b5-1
$404.5K
2.8K sh · $146.35
Own -2%
-
Other·D
Chairman, CEO and President · 10b5-1
$2.5M
17.4K sh · $146.15
Own -14%
-
Exercise·M
Chairman, CEO and President · 10b5-1
$2.5M
20.2K sh · $126.16
Own +19%
-
Sell·S
EVP, Chief Revenue Officer · 10b5-1
$11.1K
75 sh · $147.35
Own -0%
-
Grant·A
Director
$31.3K
210 sh · $149.04
Own +108%
-
Grant·A
Director
$15.6K
105 sh · $149.04
Own +3%
-
Grant·A
Vitor Roque KEY
EVP & Chief Financial Officer
$0
1.7K sh
Own +26%
-
Sell·S
EVP, Chief Revenue Officer · 10b5-1
$11.2K
74 sh · $151.94
Own -0%
-
Other·F
EVP and Chief People Officer
$0
1.1K sh
Own -5%
-
Sell·S
EVP, Chief Revenue Officer · 10b5-1
$11.8K
75 sh · $156.83
Own -0%
-
Grant·A
EVP and General Counsel
$0
7.5K sh
Own New
-
Grant·A
Vitor Roque KEY
Interim CFO
$0
931 sh
Own +17%
-
Grant·A
SVP Controller & CAO
$0
931 sh
Own +39%
-
Sell·S
EVP, Chief Revenue Officer · 10b5-1
$13.6K
75 sh · $181.84
Own -0%
-
Sell·S
Director
$174.0K
953 sh · $182.61
Own -3%
-
Grant·A
Director
$20.2K
100 sh · $201.91
Own New
-
Grant·A
Director
$6.1K
30 sh · $201.91
Own +2%
-
Grant·A
Christopher Ian Montague Jones
Director
$54.9K
272 sh · $201.91
Own +2%
-
Grant·A
Director
$0
1.1K sh
Own +14%
-
Grant·A
Director
$0
1.1K sh
Own +12%
-
Grant·A
Director
$0
1.1K sh
Own +28%
-
Grant·A
Director
$0
1.1K sh
Own +18%
-
Grant·A
Director
$0
1.1K sh
Own +31%
-
Grant·A
Director
$0
1.1K sh
Own +607%
-
Grant·A
Christopher Ian Montague Jones
Director
$0
1.1K sh
Own +5%
-
Grant·A
Director
$0
1.1K sh
Own +2%
-
Grant·A
Director
$0
1.1K sh
Own +3%
-
Grant·A
Director
$0
1.1K sh
Own +48%
-
Grant·A
Director
$0
1.1K sh
Own +607%
-
Sell·S
EVP, CRO & Pres. Life Sciences · 10b5-1
$15.2K
75 sh · $202.73
Own -0%
-
Other·F
SVP Controller & CAO
$0
84 sh
Own -4%
-
Exercise·M
EVP & Pres Med.Essntl&BioPharm · 10b5-1
$0
3.1K sh
Own New
-
Sell·S
EVP & Pres Med.Essntl&BioPharm · 10b5-1
$208.6K
1.0K sh · $206.54
Own -8%
-
Sell·S
EVP & Pres Med.Essntl&BioPharm · 10b5-1
$125.4K
600 sh · $209.00
Own -4%
-
Other·D
EVP & Pres Med.Essntl&BioPharm · 10b5-1
$512.9K
2.5K sh · $209.00
Own -15%
-
Exercise·M
EVP & Pres Med.Essntl&BioPharm · 10b5-1
$512.8K
3.1K sh · $167.91
Own +23%
-
Other·F
EVP and Chief ISC Officer
$0
44 sh
Own -0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Michael David Garrison 10b5-1 | Sell S | 1.1K | $166.6K |
| Jun 1, 2026 | Peter Menziuso KEY | Grant A | 14.3K | $0 |
| Jun 1, 2026 | Thomas E Polen Jr KEY 10b5-1 | Exercise M | 20.2K | $0 |
| Jun 1, 2026 | Thomas E Polen Jr KEY 10b5-1 | Sell S | 2.8K | $404.5K |
| Jun 1, 2026 | Thomas E Polen Jr KEY 10b5-1 | Other D | 17.4K | $2.5M |
| Jun 1, 2026 | Thomas E Polen Jr KEY 10b5-1 | Exercise M | 20.2K | $2.5M |
| May 26, 2026 | Michael Feld 10b5-1 | Sell S | 75 | $11.1K |
| May 8, 2026 | Robert Luther Huffines | Grant A | 210 | $31.3K |
| May 8, 2026 | Carrie L Byington | Grant A | 105 | $15.6K |
| May 7, 2026 | Vitor Roque KEY | Grant A | 1.7K | $0 |
| Apr 27, 2026 | Michael Feld 10b5-1 | Sell S | 74 | $11.2K |
| Apr 6, 2026 | Shana Carol Neal | Other F | 1.1K | $0 |
| Mar 26, 2026 | Michael Feld 10b5-1 | Sell S | 75 | $11.8K |
| Mar 16, 2026 | Lanesha Minnix | Grant A | 7.5K | $0 |
| Mar 2, 2026 | Vitor Roque KEY | Grant A | 931 | $0 |
| Mar 2, 2026 | Pamela L. Spikner | Grant A | 931 | $0 |
| Feb 26, 2026 | Michael Feld 10b5-1 | Sell S | 75 | $13.6K |
| Feb 18, 2026 | Bertram L Scott | Sell S | 953 | $174.0K |
| Feb 4, 2026 | Robert Luther Huffines | Grant A | 100 | $20.2K |
| Feb 4, 2026 | Carrie L Byington | Grant A | 30 | $6.1K |
| Feb 4, 2026 | Christopher Ian Montague Jones | Grant A | 272 | $54.9K |
| Jan 27, 2026 | Jeffrey William Henderson | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Andrew R Eckert | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Carrie L Byington | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Gregory Hayes | Grant A | 1.1K | $0 |
| Jan 27, 2026 | William M Brown | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Robert Luther Huffines | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Christopher Ian Montague Jones | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Timothy M Ring | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Bertram L Scott | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Joanne Waldstreicher | Grant A | 1.1K | $0 |
| Jan 27, 2026 | Jacqueline Wright | Grant A | 1.1K | $0 |
| Jan 26, 2026 | Michael Feld 10b5-1 | Sell S | 75 | $15.2K |
| Jan 21, 2026 | Pamela L. Spikner | Other F | 84 | $0 |
| Jan 15, 2026 | Michael David Garrison 10b5-1 | Exercise M | 3.1K | $0 |
| Jan 15, 2026 | Michael David Garrison 10b5-1 | Sell S | 1.0K | $208.6K |
| Jan 15, 2026 | Michael David Garrison 10b5-1 | Sell S | 600 | $125.4K |
| Jan 15, 2026 | Michael David Garrison 10b5-1 | Other D | 2.5K | $512.9K |
| Jan 15, 2026 | Michael David Garrison 10b5-1 | Exercise M | 3.1K | $512.8K |
| Jan 3, 2026 | David Shan | Other F | 44 | $0 |
About BDX insider trading
This page tracks insider transactions for BECTON DICKINSON & CO (BDX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.